drugset / Trial / NCT05916729

Use of Maqui Berry Extract in Treating Oral Candidiasis in Diabetes Mellitus Patients and Systemically Healthy Persons

NCT05916729

Phase 4 Unknown 90 enrolled University of Belgrade
RandomizedParallel-groupOpen-labelTreatment

Summary

Fungi from the genus Candida present the saprophytic flora of the cavity. This saprophytic yeast can cause different form of oral infections at immunocompromised patients as well as at subjects with impaired local oral microbiota e.g. wearers of dentures. The most common cause of oral candidiasis is Candida albicans, but recently, non-albicans species has also been commonly isolated. One of the reasons for growing frequency of non-albicans species is traditional antifungal therapy. Standard antifungal therapy, which means elimination of yeasts, lead to antimicrobial resistance, dysbiosis and higher incidence of non-albicans species In order to overcome these limitations, the new antimicrobial therapy is based on anti-virulence strategy. This approach relays on disarming the microorganism, instead of killing or stopping their growth, which is especially important for saprophytes. In case of Candida albicans the main goal is preventing transition from cell to hyphal form.

Timeline

Start
2021-05-01
Primary completion
2024-12-31
Completion
2025-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Maqui Berry extract Unknown Oral
Subject Miconazole Small molecule Oral

Indications